Blackstone Life Sciences

Anthos abelacimab trial, Blackstone ex-Novartis drug, Xarelto bleeding comparison, Anti-Factor XI/XIa antibody, Thrombosis without hemostasis, Novartis MAA868 history, Anthos phase 3 studies,

Anthosā€™ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial

Anika Sharma

Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...